Physician profile
Michael Tran
NPI 1073552295
$15,860.07
in general payments reported to CMS, 2019-2025
47 companies · $4,267 in 2025
The $4,267 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,535 · 2020: $1,111 · 2021: $1,745 · 2022: $1,422 · 2023: $2,176 · 2024: $1,604 · 2025: $4,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,341 · Consulting Fee: $2,625 · Travel and Lodging: $81.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,340.58 |
| Consulting Fee | $2,625.00 |
| Travel and Lodging | $81.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $2,706.90 | 2025 | |
| Medtronic Minimed, INC. | $1,806.81 | 2019-2020 | |
| Lilly USA, LLC | $1,738.20 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $1,208.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $855.10 | 2019-2025 | Tepezza, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $791.38 | 2019-2025 | |
| Mannkind Corporation | $657.12 | 2019-2025 | Afrezza |
| Abbvie INC. | $577.92 | 2019-2025 | Synthroid |
| Astrazeneca Pharmaceuticals LP | $423.89 | 2019-2022 | |
| Medtronic, INC. | $395.28 | 2021-2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.54 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $364.05 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $354.52 | 2020-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $349.62 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $322.18 | 2021-2025 | Gvoke Hypopen, Keveyis |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.